CytoMed Therapeutics (NASDAQ:GDTC) has announced the signing of a five-year business and research collaboration agreement with the SunAct Cancer Institute to investigate the efficacy, safety, tolerability, and potency of CytoMed’s allogeneic gamma delta T cells in treating various cancers, including solid tumours, in a Phase II clinical trial in India.
CytoMed reports that both companies will sponsor the clinical trial, which will be led by SunAct founder, medical oncologist, and immunotherapy specialist Dr. Vijay Patil. Under the agreement, CytoMed will provide technical support and manufacture the allogenic gamma delta T cells.
In a statement, Dr. Patil said, “This collaboration with CytoMed will provide an alternative treatment for a wide range of solid cancers at a reduced cost to an increasing host of the population of India suffering from the effects of cancer.”
“We aim to provide much-needed access to and treatment for cancer at an affordable cost and to contribute to an increasing and much-needed global data pool in our quest for a solution to fight cancer,” Dr. Patil added.
